Ep. 376 - M&A momentum: 3Q public markets preview

BioCentury This Week by BioCentury

Jul 13, 202633:01Science & Medicine

M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can ca...

Related Episodes

Continue listening to more episodes from BioCentury This Week.

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Oct 5, 2026 - 30:09

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis st...

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Sep 30, 2026 - 34:28

Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging...

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Sep 28, 2026 - 37:22

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropath...

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Sep 21, 2026 - 32:00

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, tes...

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Sep 14, 2026 - 30:59

Note: This episode was briefly published with an incorrect audio file, which has since been corrected. FD...

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Sep 8, 2026 - 35:05

A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis,...

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Aug 31, 2026 - 35:37

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals...

Ep. 384 - Back to School Special: The global FIH trials race

Aug 27, 2026 - 42:31

China has changed the global narrative on delivering early human clinical data, with a new bar for speed...